Skip to main
DVAX

Dynavax Technologies (DVAX) Stock Forecast & Price Target

Dynavax Technologies (DVAX) Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 25%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 25%

Bulls say

Dynavax Technologies Corp is experiencing positive developments with its vaccine candidates, particularly the shingles vaccine Z-1018, which shows vaccine response rates (VRR) comparable to those of Shingrix, but with significantly better tolerability. The encouraging results regarding CD4+ T-cell responses and tolerability for Z-1018 align well with the company’s goals for immunogenicity, indicating a strong potential for market acceptance. Furthermore, Dynavax continues to generate substantial revenue from its existing products, CpG 1018 and HEPLISAV-B, supporting a robust financial foundation as it advances its pipeline.

Bears say

Dynavax Technologies Corp faces significant risks related to its clinical development pipeline, as potential candidates may not meet efficacy endpoints or could present safety issues, jeopardizing their approval and commercialization. Furthermore, the company may encounter challenges in effectively commercializing its proprietary candidates due to unfavorable market conditions, strong competition, or internal factors, which could further hinder future revenue generation. Additionally, the possibility of not securing acceptable partnership terms for its candidates adds another layer of risk, threatening the successful launch and adoption of its products.

Dynavax Technologies (DVAX) has been analyzed by 4 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 25% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dynavax Technologies (DVAX) Forecast

Analysts have given Dynavax Technologies (DVAX) a Hold based on their latest research and market trends.

According to 4 analysts, Dynavax Technologies (DVAX) has a Hold consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dynavax Technologies (DVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.